Thematic area:
Smart Implants and Devices
Product:
A self-adapting, AI-enhanced soft robotic drug delivery cannula that senses and responds to the foreign body response (FBR). The system adjusts its actuation profile in real-time to maintain consistent drug delivery despite tissue encapsulation.
Market:
Highly relevant to chronic disease management markets, especially the €2B insulin pump and consumables sector. Also applicable to implantable infusion therapies used in oncology, neurology, and pain management.
Fit:
Implanted drug delivery systems routinely fail due to fibrotic encapsulation. AFS is the first solution to continuously sense and adapt to FBR, extending device lifespan and improving therapeutic reliability. Strong potential for commercial translation into diabetes management and wider long-term drug delivery markets.
